24.99
Rapport Therapeutics Inc Borsa (RAPP) Ultime notizie
Multi factor analysis applied to Rapport Therapeutics Inc.CPI Data & Reliable Breakout Forecasts - newser.com
Insider Sell: David Bredt Sells 8,500 Shares of Rapport Therapeutics Inc (RAPP) - GuruFocus
How to recover losses in Rapport Therapeutics Inc. stock2025 Trading Volume Trends & Real-Time Market Sentiment Alerts - newser.com
What candlestick patterns are forming on Rapport Therapeutics Inc.July 2025 Analyst Calls & Low Risk High Reward Ideas - newser.com
Rapport Therapeutics Inc. stock chart pattern explainedTrade Analysis Report & Short-Term Trading Opportunity Alerts - newser.com
Has Rapport Therapeutics Inc. found a price floorEarnings Summary Report & Community Supported Trade Ideas - newser.com
Published on: 2025-10-15 06:26:38 - newser.com
Smart tools for monitoring Rapport Therapeutics Inc.’s price actionWeekly Market Summary & Reliable Breakout Stock Forecasts - newser.com
Why Rapport Therapeutics Inc. stock could be next big winner2025 Top Gainers & Reliable Price Breakout Signals - newser.com
Can volume confirm reversal in Rapport Therapeutics Inc.Wall Street Watch & Risk Managed Trade Strategies - newser.com
Published on: 2025-10-14 03:02:31 - newser.com
Volatility clustering patterns for Rapport Therapeutics Inc.Stop Loss & Verified Momentum Stock Watchlist - newser.com
Analysts Set Rapport Therapeutics, Inc. (NASDAQ:RAPP) PT at $35.33 - Defense World
Statistical indicators supporting Rapport Therapeutics Inc.’s strengthSell Signal & AI Based Trade Execution Alerts - newser.com
Analyzing net buyer seller activity in Rapport Therapeutics Inc.Trade Analysis Summary & Safe Entry Trade Reports - newser.com
Is Rapport Therapeutics Inc. trending in predictive chart models2025 Momentum Check & Weekly Sector Rotation Insights - newser.com
Published on: 2025-10-12 22:23:14 - newser.com
Identifying reversal signals in Rapport Therapeutics Inc.Weekly Trading Summary & Risk Controlled Stock Pick Alerts - newser.com
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Key metrics from Rapport Therapeutics Inc.’s quarterly dataJuly 2025 Levels & Risk Controlled Daily Plans - newser.com
Weiss Ratings Reaffirms Sell (D-) Rating for Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Applying big data sentiment scoring on Rapport Therapeutics Inc.Quarterly Profit Summary & Weekly Watchlist of Top Performers - newser.com
Rapport Therapeutics, Inc. (RAPP) Stock Analysis: Unveiling Its 93.40% Potential Upside in the Booming Biotech Sector - DirectorsTalk Interviews
Should you hold or exit Rapport Therapeutics Inc. nowMarket Trend Review & Real-Time Volume Analysis Alerts - newser.com
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 2.3%What's Next? - MarketBeat
What analysts say about Rapport Therapeutics Inc stockStock Buy Signals & Invest Now – Opportunity Window Closing - earlytimes.in
Full technical analysis of Rapport Therapeutics Inc. stockJuly 2025 Levels & Verified Chart Pattern Trade Signals - newser.com
Applying Elliott Wave Theory to Rapport Therapeutics Inc.Weekly Volume Report & Weekly Chart Analysis and Guides - newser.com
Momentum divergence signals in Rapport Therapeutics Inc. chartJuly 2025 Gainers & Weekly High Conviction Trade Ideas - newser.com
How institutional ownership impacts Rapport Therapeutics Inc. stockWeekly Trend Recap & Capital Efficient Trade Techniques - newser.com
Using data filters to optimize entry into Rapport Therapeutics Inc.July 2025 Closing Moves & Target Return Focused Stock Picks - newser.com
Rapport Therapeutics, Inc. (RAPP) Stock Analysis: Exploring an 81% Upside Potential in CNS Therapeutics - DirectorsTalk Interviews
Rapport Therapeutics (RAPP) Is Up 14.3% After Positive RAP-219 Phase 2a Results in Epilepsy - Sahm
Is Rapport Therapeutics Inc. stock recession proofMarket Risk Report & Verified Short-Term Plans - newser.com
Rapport Therapeutics (NASDAQ:RAPP) Shares Down 7.3%Here's What Happened - MarketBeat
Why Rapport Therapeutics (RAPP) Is Up 6.3% After Positive Phase 2a Epilepsy Drug Results and Analyst Optimism - Yahoo Finance
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):